pharmaceutical industry

First Opinion By Henry A. Waxman and Bill Corr

Waste from pharmaceutical plants in India and China promotes antibiotic-resistant superbugs

Pharmalot By Ed Silverman

The curious case of the $9,500 skin gel

Business By Damian Garde

The EpiPen was her ‘baby.’ Now this pharma CEO is in the hot seat over price hikes

Politics By Dylan Scott

Donald Trump’s trade talk is making the drug industry uneasy

Politics By Sheila Kaplan

5 ways drug makers and the health care industry are shaping campaigns

In the Lab By Helen Branswell

The race for a Zika vaccine is intense. But it may be missing the most important players

Don't Miss By Damian Garde

How biotech executives profit from legal insider trades

Biotech By Damian Garde

There’s a possible cure for ‘bubble boy’ disease. It will cost $665,000

The Pharmalot View By Ed Silverman

The ‘gouge factor’: Big companies want transparency in drug price negotiations

Business By Rebecca Robbins

Why Democratic convention viewers saw so many drug ads

First Opinion By Charles D. Rosen

Say what you will about Donald Trump. He’s right about drug companies

Don't Miss By Dylan Scott

Billionaire businessman Mark Cuban has something to say about drug prices

Biotech By Damian Garde

Could a molecular ‘on-off switch for agony’ lead to a safer painkiller?

Business By Charles Ornstein and Ryann Grochowski Jones — ProPublica

Drug and device makers find receptive audience at for-profit, Southern hospitals

The Pharmalot View By Ed Silverman

Drug industry overstates impact of patent reviews on innovation

Biotech By Meghana Keshavan and Rebecca Robbins

Post-Brexit, will the European Medicines Agency be homeless?

Politics By Dylan Scott

Supreme Court’s ruling in patent case a blow to drug industry